A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Active, not recruiting · Phase 3 · NCT03336333
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $809,965
- U.S. investigators named
- 15
- Sites paid
- 16
- Planned or actual enrollment
- 590
About the trial
- Sponsor
- BeiGene
- Tested
- Zanubrutinib (drug), Bendamustine (drug), Rituximab (drug), Venetoclax (drug)
- Dates
- Started 2017-10-31; completion 2027-10-31
- Results posted
- Yes
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
From ClinicalTrials.gov, last updated 2026-03-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $809,965 in research payments for this study in 2025 (69 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Shuo Ma, M.D., PH.D. Hematology & Oncology · Chicago, IL
- Jennifer R. Brown, MD PHD Hematology · Boston, MA
- Brad S. Kahl, MD Medical Oncology · Saint Louis, MO
- Danielle M. Brander, M.D. Hematology & Oncology · Durham, NC
- Benjamin B. Freeman, M.D. Medical Oncology · Morristown, NJ
- Edwin C. Kingsley, MD Hematology & Oncology · Las Vegas, NV
- Paul M. Barr, MD Hematology · Rochester, NY
- Nicole Lamanna, MD Medical Oncology · New York, NY
- Jonah Shulman Medical Oncology · New York, NY
- Stephen E. Spurgeon, MD Internal Medicine · Portland, OR
- Bipinkumar Amin, MD Hematology & Oncology · Watertown, SD
- Donald P. Quick, MD Hematology & Oncology · Lubbock, TX
- Craig A. Portell, M.D. Hematology & Oncology · Charlottesville, VA
- Solomon A. Graf, M.D. Hematology & Oncology · Seattle, WA
- Mazyar Shadman, MD,MPH Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana Farber Mass General Brigham Cancer Care Inc $226,799
- Columbia University $146,062
- Ohsu Hospital and Clinics, OR $134,808
- Northwestern University $80,799
- Fred Hutchinson Cancer Center $52,549
- Duke University , $33,441
- Covenant Health - Joe Arrington Cancer Research Treatment Center $32,569
- Strong Memorial Hospital, NY $30,431
- Icahn School of Medicine at Mount Sinai $25,660
- VA Pugent Sound Health Care System $14,200
- Comprehensive Cancer Centers of Nevada - Central Valley $10,109
- University of Virginia Medical Center, VA $9,382
- Washington University $5,351
- Prairie Lakes Health Care System, Inc. $3,384
- Summit Medical Group, P.a. $2,969
- Summit Medical Group $1,452
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.